AzTrials
AzTrials

Epithelial Ovarian CancerGREATNCT04027868

Genomic BRCA and Extensive ovArian Cancer Testing

An observational study of Epithelial Ovarian Cancer and Peritoneal Cancer, run by ARCAGY/ GINECO GROUP at 137 sites in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a prospective observational French multicenter cohort in patients with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014). Read more about this study

Who is it for?
Ages 18 years and older, women only
How many people
1,500 participants
Where
137 sitesFrance
Study dates
6 Dec 2019to 7 Nov 2022
How long will I take part?
10 Years
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014)

Who may be able to join

  • Patient older than 18 years.
  • Patient with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014)
  • Patient in first line therapy
  • Available tumor sample fixed in formalin and included in paraffin (FFPE):
  • in pre-chemotherapy, insofar as possible
  • having a sufficient tumor surface, with a final cellularity of at least 20%
Show all 9Show fewer
  • Identification of a molecular genetics' cancer platform participant in GREAT and an onco-geneticists team working with the investigator team
  • Patient consenting her data to be collected and submitted through an automated processing
  • Patient beneficiary from the French social security

Who cannot join

  • Patient with a mucinous ovarian carcinoma
  • Patient pregnant or breastfeeding
  • Patient under legal protection (guardianship or court order) or unable to consent

Trial locations and contacts

137 sites in 1 country.

137 sites in 1 country

France137 sites

  • Centre de Radiothérapie et d'Oncologie de Moyenne Garonne (CROMG)

    Agen, 47000

  • Hôpital Privé d'Aix en Provence

    Aix-en-Provence, 13080

  • Centre Hospitalier Général d'Aix-en-Provence

    Aix-en-Provence

  • CHU Amiens

    Amiens

  • Clinique Victor PAUCHET

    Amiens

  • Institut de Cancérologie de l'Ouest - ICO

    Angers

  • Hôpital Privé d'Antony - Ramsay Santé

    Antony, 92160

  • CH Arras

    Arras

  • CH Auxerre

    Auxerre

  • Institut Sainte Catherine

    Avignon

  • Clinique Belharra

    Bayonne, 64100

  • CH Côte Basque

    Bayonne

  • Centre Hospitalier de Beauvais

    Beauvais, 60021

  • CHRU Jean Minjoz

    Besançon

  • Reims Icone

    Bezannes, 51100

  • CH de Blois

    Blois

  • Hôpital Avicenne

    Bobigny, 93009

  • CHU de Bordeaux - Hôpital Pellegrin

    Bordeaux

  • Clinique Tivoli

    Bordeaux

  • Institut Bergonié

    Bordeaux

  • Polyclinique Bordeaux Nord

    Bordeaux

  • Centre Hospitalier Fleyriat - BOURG-EN-BRESSE

    Bourg-en-Bresse

  • CHU Brest

    Brest

  • Hôpital Femme Mère Enfant

    Bron, 89500

  • Centre François Baclesse

    Caen

  • Centre Maurice Tubiana

    Caen

  • CH de Cahors

    Cahors

  • CH Carcassonne

    Carcassonne

  • Hôpital Général de Castres

    Castres

  • Medipole de Savoie

    Challes-les-Eaux

  • CH Chalon sur Saone

    Chalon-sur-Saône

  • CH Metropole Savoie

    Chambéry

  • Centre d'Oncologie et de Radiothérapie 37

    Chambray-lès-Tours

  • Centre Hospitalier de Chateauroux

    Châteauroux, 36000

  • CHPC - Hôpital Louis Pasteur

    Cherbourg

  • CH Cholet

    Cholet

  • Hôpital Antoine Béclère

    Clamart

  • Centre Jean Perrin

    Clermont-Ferrand

  • CH Alpes Léman

    Contamine-sur-Arve

  • Centre Hospitalier Sud Francilien (Site Gilles de Corbeil)

    Corbeil-Essonnes, 91106

  • Clinique des Cèdres

    Cornebarrieu, 31700

  • Clinique de Flandre

    Coudekerque-Branche

  • Groupe Hospitalier public du Sud de l'Oise (GHPSO)

    Creil

  • CHI Creteil

    Créteil

  • Centre Georges François Leclerc

    Dijon

  • CHU Dijon

    Dijon

  • Institut de Cancérologie de Bourgogne - GRReCC

    Dijon

  • Clinique du Mousseau (CMCO) - Ramsay Santé

    Évry, 91000

  • Centre Hospitalier Intercommunal de Fréjus Saint Raphael

    Fréjus, 83600

  • GH Mutualiste de Grenoble

    Grenoble

  • Hôpital Privé Drôme Ardèche - Clinique Pasteur

    Guilherand-Granges, 07500

  • Centre Hospitalier Marne-la-Vallée

    Jossigny

  • Centre Hospitalier Départemental de Vendée

    La Roche-sur-Yon, 85925

  • CHU Grenoble Alpes - Site Nord (La Tronche)

    La Tronche

  • Hôpital André Mignot

    Le Chesnay

  • Les Hôpitaux de Chartres

    Le Coudray

  • Hôpital Privé de l'Estuaire

    Le Havre, 76600

  • CHU Bicêtre

    Le Kremlin-Bicêtre

  • Centre Hospitalier du Mans

    Le Mans

  • CH de Lens

    Lens

  • Institut Hospitalier Franco-Britannique

    Levallois-Perret

  • Polyclinique de Limoges - Clinique Chenieux

    Limoges, 87039

  • CHU de Limoges - Hôpital Dupuytren

    Limoges, 87042

  • Groupe Hospitalier Bretagne Sud - Hôpital du Scorff

    Lorient

  • HCL - Hôpital de la Croix Rousse

    Lyon, 60004

  • Clinique de l'infirmerie Protestante

    Lyon, 69300

  • Centre Léon Bérard

    Lyon

  • Clinique de la Sauvegarde

    Lyon

  • Hôpital Privé Jean Mermoz

    Lyon

  • APHM - Hôpital de la Timone

    Marseille

  • Hôpital Nord

    Marseille

  • Institut Paoli Calmettes

    Marseille

  • Centre Hospitalier Layné

    Mont-de-Marsan, 40024

  • Hôpital Nord Franche Comté

    Montbéliard

  • CH de Montelimar

    Montélimar

  • Centre de Cancérologe du Grand Montpellier

    Montpellier

  • CHRU de Montpellier - Hôpital Saint-Eloi

    Montpellier

  • ICM - Val d'Aurelle

    Montpellier

  • Centre Azuréen de Cancérologie

    Mougins, 06250

  • Oracle - Centre d'Oncologie de Gentilly

    Nancy

  • Hôpital Privé du Confluent

    Nantes

  • Clinique Hartmann

    Neuilly-sur-Seine

  • Centre Antoine Lacassagne

    Nice, 06000

  • Institut de Cancérologie du Gard - ONCOGARD

    Nîmes, 30029

  • Institut de Cancérologie du Gard

    Nîmes

  • CHR Orléans

    Orléans

  • Hôpital de la Pitié Salpétrière

    Paris, 75000

  • GH Saint Joseph

    Paris

  • Groupe Hospitalier Diaconesses - Croix Saint-Simon

    Paris

  • HEGP

    Paris

  • Hôpital Bichat

    Paris

  • Hôpital Cochin

    Paris

  • Hôpital Lariboisière

    Paris

  • Institut Curie

    Paris

  • Institut Mutualiste Montsouris

    Paris

  • CH Pau

    Pau

  • Clinique Francheville

    Périgueux

  • Centre Catalan d'Oncologie

    Perpignan

  • CH Perpignan

    Perpignan

  • HCL - Centre Hospitalier Lyon Sud

    Pierre-Bénite, 69006

  • Centre CARIO-HPCA

    Plérin

  • Hôpital de la Milétrie

    Poitiers

  • CH René Dubos

    Pontoise

  • CH Annecy Genevois

    Pringy

  • Clinique de la Croix du Sud

    Quint-Fonsegrives

  • Centre Eugène Marquis

    Rennes

  • Hôpitaux Drôme Nord - Centre Hospitalier Romans

    Romans-sur-Isère, 26100

  • Centre Henri Becquerel

    Rouen, 76000

  • Clinique Mathilde

    Rouen, 76100

  • Centre Frédéric Joliot

    Rouen

  • Centre Hospitalier Yves Le Foll

    Saint-Brieuc

  • Institut Curie - Site Saint Cloud

    Saint-Cloud, 92210

  • Hôpital Privé de La Loire Saint-Etienne

    Saint-Etienne, 42100

  • Centre Hospitalier Privé Saint Grégoire

    Saint-Grégoire

  • Institut de Cancérologie de l'Ouest - ICO

    Saint-Herblain

  • HIA Begin

    Saint-Mandé

  • Clinique Mutualiste de l'Estuaire

    Saint-Nazaire

  • CHU Saint-Etienne - Pôle de Cancérologie

    Saint-Priest-en-Jarez

  • Centre Médicale Sainte Feyre Alfred Leune

    Sainte-Feyre, 23000

  • Clinique Charcot

    Sainte-Foy-lès-Lyon

  • Institut de Cancérologie Paris Nord

    Sarcelles

  • CH Sens

    Sens

  • CH Broussais

    St-Malo

  • ICANS - Institut de cancérologie Strasbourg Europe

    Strasbourg, 67037

  • Hôpital Foch

    Suresnes

  • CHR Metz-Thionville / Hôpital de Mercy

    Thionville, 45001

  • Hôpitaux du Léman

    Thonon-les-Bains

  • Hôpital d'Instruction des Armées Saint-Anne

    Toulon, 83800

  • Clinique Pasteur - Groupe Oncorad Garonne

    Toulouse

  • Clinique Pasteur - Oncosud

    Toulouse

  • Institut Claudius Regaud

    Toulouse

  • CHU Bretonneau

    Tours

  • Centre Hospitalier de Troyes

    Troyes

  • CH Jean Bernard

    Valenciennes

  • Clinique des Dentellières

    Valenciennes

  • Institut de Cancérologie de Lorraine (ICL) - Centre Alexis Vautrin

    Vandœuvre-lès-Nancy

  • Gustave Roussy

    Villejuif

Other trials in France

About this study

Official title: Cohort Study to Evaluate the Clinical Features of Patients With Epithelial Ovarian Cancer Depending on Tumoral Mutation of BRCA or Beyond BRCA Genomic Molecular Abnormalities

This is a prospective observational French multicenter cohort in patients with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014). The objective is to constitute a clinico-biological database that allows to correlate clinical and progressive features of ovarian cancer patients based on tumor genomics and molecular detected abnormalities.

Read the detailed description

This is a prospective observational French multicenter cohort in patients with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014). The objective is to constitute a clinico-biological database that allows to correlate clinical and progressive features of ovarian cancer patients based on tumor genomics and molecular detected abnormalities.

Medical subject headings
Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Correlation between Progression Free Survival (PFS) and the detected tumor genetic abnormalities

    Measured: From baseline until the date of progression or death, which ever occurs earlier, assessed up to 10 years

Secondary outcomes (6)

  1. Correlation between age and the detected tumor genetic abnormalities

    Measured: Baseline

  2. Correlation between histology status and the detected tumor genetic abnormalities

    Measured: Baseline

  3. Correlation between FIGO stage and the detected tumor genetic abnormalities

    Measured: Baseline

  4. Correlation between surgery resection status and the detected tumor genetic abnormalities

    Measured: Up to 10 years

  5. Correlation between treatment response and the detected tumor genetic abnormalities

    Measured: Up to 10 years

  6. Correlation between Overall survival (OS) and the detected tumor genetic abnormalities

    Measured: From baseline to death, assessed up to 10 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Jul 2019
  2. Study start6 Dec 2019
  3. Primary completion7 Nov 2022
  4. Study completion7 Nov 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
1,500 participants (actual)
Target duration
10 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT04027868
Sponsor's protocol ID
GINECO-OV128
Other IDs
2019-A01190-57, 19.06.45
Acronym
GREAT
Status last verified
Jun 2026
First submitted
18 Jul 2019
Last updated
8 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Epithelial Ovarian Cancer and Peritoneal Cancer, run by ARCAGY/ GINECO GROUP at 137 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 137 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Correlation between Progression Free Survival (PFS) and the detected tumor genetic abnormalities (time frame: From baseline until the date of progression or death, which ever occurs earlier, assessed up to 10 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04027868.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jun 2026; AzTrials last refreshed its copy on 4 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in